MedWatch

Fruergaard on US rebate reform: "It will create a gap somewhere else"

Novo Nordisk and its rivals support a US proposal to criminalize discounts to middlemen in the public health channel Medicare from 2020. However, Novo's CEO, Lars Fruergaard Jørgensen, warns that the initiative will create a gap somewhere else in the budget.

Foto: Scanpix/Liselotte Sabroe

The US Ministry of Health has made a proposal to prohibit drug groups from offering discounts to the pharmacy benefit managers (PBMs) via the public health channel Medicare Part D as of 2020.

The initiative is welcomed by the world's three leading insulin companies that have faced criticism in the ongoing debate about high medicines prices in the US and the rebate system that, paradoxically, contributes to the increased gross prices.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier